Free tool
FAERS Monitor: Differin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020748 or its brand name (Differin, Adapalene). Reports on generic versions are filed under their own applications.
Reports
6,328
Serious
864
14% of reports
Hospitalization
305
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,537
- dry skin941
- skin burning sensation574
- acne553
- skin irritation535
- erythema504
- condition aggravated442
- rash405
- skin exfoliation352
- therapy cessation227
- pruritus205
- hypersensitivity182
- pain124
- pain of skin118
- inappropriate schedule of product administration90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 12 |
| 2006 | 26 |
| 2007 | 9 |
| 2008 | 28 |
| 2009 | 26 |
| 2010 | 33 |
| 2011 | 78 |
| 2012 | 62 |
| 2013 | 58 |
| 2014 | 71 |
| 2015 | 118 |
| 2016 | 118 |
| 2017 | 72 |
| 2018 | 82 |
| 2019 | 175 |
| 2020 | 128 |
| 2021 | 108 |
| 2022 | 155 |
| 2023 | 195 |
| 2024 | 832 |
| 2025 | 878 |
| 2026 | 3,051 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,831 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin irritationSignal | 535 | 39.3 | 36.2 | 19,723 |
| skin burning sensationSignal | 574 | 26.8 | 24.8 | 14,186 |
| acneSignal | 553 | 24.4 | 22.5 | 12,348 |
| dry skinSignal | 941 | 23.6 | 22.2 | 20,319 |
| therapy cessationSignal | 227 | 14.8 | 13.0 | 2,892 |
| pain of skinSignal | 118 | 14.6 | 12.2 | 1,480 |
| skin exfoliationSignal | 352 | 13.9 | 12.6 | 4,208 |
| erythemaSignal | 504 | 8.2 | 7.5 | 3,186 |
| drug ineffectiveSignal | 2,537 | 6.4 | 6.2 | 12,325 |
| condition aggravatedSignal | 442 | 4.8 | 4.4 | 1,359 |
| hypersensitivitySignal | 182 | 3.3 | 2.8 | 285 |
| rashSignal | 405 | 3.1 | 2.8 | 582 |
| pruritus | 205 | 1.8 | 1.5 | 70 |
| inappropriate schedule of product administration | 90 | 1.7 | 1.4 | 23 |
| pain | 124 | 0.7 | 0.6 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.